Pharma News

Lifirafenib maleate, what is the likelihood that the drug will be approved?

Lifirafenib maleate is under clinical development by BeiGene and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lifirafenib maleate’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lifirafenib maleate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lifirafenib maleate overview

Lifirafenib maleate is under development for the treatment of solid tumors like BRAF and non-BRAF mutated melanoma, thyroid cancer, ovarian cancer, endometrial cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma and non-small cell lung cancer. The drug candidate is administered orally. It targets both epidermal growth factor receptor (EGFR) and B-RAF kinase.

BeiGene overview

BeiGene is a biotechnology company. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers BRUKINSA, a BTK (Bruton’s tyrosine kinase) inhibitor against mantle cell lymphoma (MCL). BeiGene is investigating Zanubrutinib (BGB-3111), a small molecule inhibitor of BTK to treat B cell malignancies; Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. It seeks to work in partnership with academia, biotechnology and pharmaceutical companies to develop treatments for cancer patients. The company has operations in the US, Australia, Germany, Spain Switzerland, and Italy. BeiGene is headquartered in Beijing, China.

Quick View Lifirafenib maleate LOA Data

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
Key Developers
Highest Development Stage

Source link
#Lifirafenib #maleate #likelihood #drug #approved

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *